GlassScriptPhysician profile
Steven L Armus
NPI 1982601704
$1,063.38
in general payments reported to CMS, 2019-2025
14 companies · $17.38 in 2025
The $17.38 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,046 · 2025: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.49 |
| Education | $207.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $228.67 | 2024 | Purified Cortrophin Gel |
| Almatica Pharma LLC | $118.96 | 2024-2025 | Loreev Xr |
| Sun Pharmaceutical Industries INC. | $114.46 | 2024 | |
| Abbvie INC. | $97.54 | 2024 | |
| Janssen Biotech, INC. | $84.99 | 2024 | Tremfya |
| Smith+Nephew, INC. | $76.45 | 2024 | Collagenase Santyl, Grafix Pl |
| Paratek Pharmaceuticals, INC. | $74.17 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $73.39 | 2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Exact Sciences Corporation | $67.66 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $43.13 | 2024 | Ozempic, Rybelsus |
| Ibsa Pharma INC. | $32.66 | 2024 | Licart, Tirosint, Flector |
| Vanda Pharmaceuticals INC. | $20.00 | 2024 | Fanapt |
| Organogenesis INC. | $15.98 | 2024 | |
| Melinta Therapeutics, LLC | $15.32 | 2024 | Orbactiv, Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Armus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.